المملكة العربية السعودية - الإنجليزية - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi-synthlabo - nalidixic acid - tablet - 500 mg

تانزانيا - الإنجليزية - Tanzania Medicinces & Medical Devices Authority

astra lifecare india ltd., india - nalidixic acid - tablets - 500 mg

أوغندا - الإنجليزية - National Drug Authority

gittoes pharmaceuticals limited; gittoes pharmaceuticals limited - nalidixic acid - oral solid ordinary tablets - 500mg

أوغندا - الإنجليزية - National Drug Authority

fourts(india) laboratories pvt ltd - nalidixic acid - oral solid ordinary tablets - 500mg

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - mefenamic acid - capsule - 250 milligram(s) - fenamates; mefenamic acid

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - mefenamic acid - film-coated tablet - 500 milligram(s) - fenamates; mefenamic acid

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) - solution for infusion - 2 mg/ml - active: ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) excipient: hydrochloric acid lactic acid sodium chloride water for injection - infections of the lower respiratory tract. in the treatment of outpatients with pneumonia due to pneumococcus, ciprofloxacin should not be used as a medicine of first choice. ciprofloxacin can be regarded as a suitable treatment for pneumonias caused by klebsiella, enterobacter, proteus, e. coli, pseudomonas, haemophilus, branhamella, legionella, and staphylococcus.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ciprofloxacin, quantity: 200 mg - injection, solution - excipient ingredients: hydrochloric acid; lactic acid; water for injections; glucose monohydrate - ciprofloxacin injection for intravenous infusion is indicated for use in the following: 1. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. 2. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems: - lower respiratory tract infections (gram-negative organisms). skin and skin structure. septicaemia. bone and joint. urinary tract. 3. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram positive infections due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ciprofloxacin, quantity: 100 mg - injection, solution - excipient ingredients: lactic acid; hydrochloric acid; water for injections; glucose monohydrate - ciprofloxacin injection for intravenous infusion is indicated for use in the following: 1. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. 2. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems: - lower respiratory tract infections (gram-negative organisms). skin and skin structure. septicaemia. bone and joint. urinary tract. 3. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram positive infections due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - ciprofloxacin 2 mg/ml - solution for infusion - 2 mg/ml - active: ciprofloxacin 2 mg/ml excipient: glucose monohydrate hydrochloric acid lactic acid water for injection - uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens.